Physician profile
David Diskin
NPI 1306843594
$1,049.11
in general payments reported to CMS, 2019-2025
11 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2021: $13.61 · 2022: $398 · 2023: $154 · 2024: $199 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $502.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $234.45 | 2022-2023 | Tepezza |
| Alcon Vision LLC | $215.65 | 2019-2025 | Lensx, Clareon, Rocklatan |
| Rxsight INC | $143.61 | 2022 | |
| Sight Sciences, INC. | $112.82 | 2022-2024 | Omni Surgical System |
| New World Medical,INC. | $96.75 | 2023-2025 | Clearpath, Streamline, Ahmed Glaucoma Valve |
| Tarsus Pharmaceuticals, INC. | $80.45 | 2024-2025 | Xdemvy |
| Abbvie INC. | $63.54 | 2023-2025 | Durysta |
| Novartis Pharmaceuticals Corporation | $46.46 | 2021-2023 | |
| Rayner Intraocular Lenses Limited | $21.02 | 2023 | Omidria, Rayone Aspheric, Rayone Emv |
| Bausch & Lomb Americas INC. | $17.58 | 2023 | Miebo |
| Allergan, INC. | $16.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Diskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.